CPB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Campbell's Co (CPB) is not a strong buy at this time for a beginner investor with a long-term strategy and $50,000-$100,000 available. The stock is currently facing declining financial performance, bearish technical indicators, and mixed sentiment from analysts. While the dividend yield of 5.89% is attractive for income-focused investors, the lack of growth catalysts and competitive pressures in its sector make it less appealing for long-term capital appreciation.
The technical indicators for CPB are bearish. The MACD histogram is negative (-0.201) and contracting, RSI is neutral at 38.37, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 26.4, with resistance at 29.356. Overall, the trend suggests weakness in the stock's price movement.
Attractive dividend yield of 5.89%, which may appeal to income-focused investors.
Hedge funds have significantly increased their buying activity, with a 10801.13% increase in the last quarter.
The company has reaffirmed its 2026 guidance, signaling stability in its operations.
Declining financial performance in Q1 2026, with revenue down 3.43% YoY, net income down 11.01% YoY, and EPS down 9.72% YoY.
Analysts have consistently lowered price targets, citing competitive pressures, sector challenges, and weak growth prospects.
Bearish technical indicators and a high probability of short-term price declines (-1.12% in the next day, -1.04% in the next week).
Mixed sentiment in the consumer staples sector, with some analysts advising a shift to healthcare stocks for better stability.
In Q1 2026, Campbell's reported declining financial metrics: Revenue dropped to $2.677 billion (-3.43% YoY), net income fell to $194 million (-11.01% YoY), EPS decreased to $0.65 (-9.72% YoY), and gross margin declined to 29.44% (-4.54% YoY). These trends indicate challenges in maintaining profitability and growth.
Analysts have a mixed to negative outlook on CPB. Recent price target adjustments have mostly been downward, with targets ranging from $26 to $38. The consensus rating is neutral to bearish, with concerns about competitive pressures, sector challenges, and limited growth catalysts.
